A Korean genetic sequencing firm has taken a step towards the commercialization of its liquid biopsy technology, which aims at detecting early stage cancer with a simple blood test and suggesting optimized treatment. Eone Diagnomics Genome Center (EDGC) announced that ...
Read More »
Creative Medical Technology Holdings announced today filing a new patent application covering nanoparticles called “exosomes” secreted by cells of its...
Read More »
Vesigen Therapeutics, a biotechnology company pioneering a novel extracellular vesicle delivery technology to develop transformative therapeutics, today...
Read More »
The present invention relates to a pharmaceutical composition for prevention or treatment of non-alcoholic steatohepatitis, the composition comprising, as an active ingredient, exosomes isolated from induced...
Read More »
Evox Therapeutics, a leading exosome therapeutics company, is pleased to announce that the Company has been granted another key patent by the European Patent Office (EPO). This new grant...
Read More »
Ymir Genomics LLC (Ymir) and the Oregon Health & Science University (OHSU) Knight Cancer Institute today announced a licensing agreement and filed patent application that seeks to protect and promote newly-discovered high value urinary biomarkers for detecting cirrhosis and/or hepatocellular ...
Read More »
Evox Therapeutics, a leading exosome therapeutics company, is pleased to announce that the Company has been granted a key patent by the United States Patent and Trademark Office (USPTO). This newly issued patent adds to the expanding foundational patent estate ...
Read More »
ILIAS Biologics, a global leader in exosome-based therapeutics, announced today that the Company has been granted a key exosome engineering patent by the United States Patent and Trademark Office (USPTO).A patent for ILIAS's exosome engineering was...
Read More »
Publication Number WO/2020/133912 Publication Date 02.07.2020 International Application No. PCT/CN2019/089478 International Filing Date 31.05.2019 Provided in the present invention is a method for simultaneously detecting exosome...
Read More »
The inventions described herein are directed to bispecific antibodies that are capable of selectively targeting exosomes by specifically binding a first exosome-associated protein and Programmed Death Ligand-1 ("PD-L1") as a second exosome-associated protein. These bispecific antibodies can disrupt the suppression of anti-tumor activity by immune cells by...
Read More »
Exosome RNA Exosome RNA Research & Industry News
